Better pharmacotherapies for epilepsy are needed for patients who are refractory to or have tolerability difficulties with current treatments. Seletracetam, a new drug in epilepsy development, is a pyrrolidone derivative structurally related to levetiracetam (trade name Keppra). It was discovered because of its high binding affinity to the synaptic vesicle 2A (SV2A) protein, which is now known to be the binding site for this family of compounds. Seletracetam shows very potent seizure suppression in models of acquired or genetic epilepsy, as well as high CNS tolerability in various animal models. Pharmacokinetic studies in animals suggest that seletracetam is rapidly and highly absorbed, with linear and time-independent pharmacokinetics. Seletracetam appears neither to inhibit nor to induce the major human drug metabolizing enzymes, and it demonstrates low plasma protein binding (Ͻ10%), which suggests a low potential for drug-drug interactions. Initial studies in humans demonstrated first-order monocompartmental kinetics with a half-life of 8 h and an oral bioavailability of Ͼ90%. Studies in healthy volunteers showed that the treatment emergent adverse events were of mild to moderate severity, were mostly of CNS origin and were resolved within 24 h. Altogether, these results suggest that seletracetam represents a promising new antiepileptic drug candidate, one that demonstrates a potent, broad spectrum of seizure protection and a high CNS tolerability in animal models, with initial clinical findings suggestive of straightforward pharmacokinetics and good tolerability.
INTRODUCTION

Epilepsy and the need for new antiepileptic drugs
Epilepsy is a chronic, often lifelong, neurological disorder that requires continuous pharmacotherapy to maintain seizure control. The age-adjusted incidence of epilepsy in developed countries is approximately 50 per 100,000 persons per year, 1 with a lifetime chance of getting epilepsy of 3-5%. 2 Epilepsy has a tremendous impact not only on the individuals afflicted with this disease, but also on their families, as well as on society in general, because of the resultant personal and financial burdens. Epilepsy is characterized by recurrent involuntary seizures, caused by disturbances in the normal electrical activity of the brain, that affect awareness, movement, or sensations. 3 These seizures may occur in just one area of the brain (partial seizures) or may affect neuronal networks throughout the brain (generalized seizures).
Pharmacotherapy is the primary treatment for epileptic patients; however, despite the introduction of secondgeneration anticonvulsants, refractory epilepsy is still a significant clinical problem. Outcome studies examining either traditional or newer anticonvulsants show that fewer than 50% of patients with epilepsy become seizure-free after beginning an initial antiepileptic medication. 4 Approximately 30% of patients (adults and children) with partial onset seizures cannot be adequately controlled with existing antiepileptic drugs (AEDs), because of either lack of efficacy or toxicity. 5 Most refractory patients have partial epilepsy; the generalized epilepsies tend to respond better to current AED therapy. 6 Furthermore, these refractory patients are at risk for cognitive and psychiatric disorders, suicide, accidental injuries, and sudden death. There continues to be a need for new antiepileptic drugs, both to improve upon the established drugs and also to treat those refractory to current pharmacotherapies.
Current drugs for the treatment of epilepsy
Classical (or first-generation) anticonvulsants, such as phenobarbital, phenytoin, carbamazepine, and valproate, are used as standard therapy in partial epilepsy. Clinical problems associated with these drugs include nonlinear pharmacokinetics, narrow therapeutic index, significant drug interactions, and adverse central nervous system effects. 7 The entrance to the market of vigabatrin, felbamate, lamotrigine, oxcarbazepine, topiramate, zonisamide, gabapentin, levetiracetam, tiagabine, and pregabalin increased the therapeutic options and improved treatment. However, most of these new drugs have a limited tolerability profile. Serious toxicity problems have been identified, including fatal idiosyncratic hepatic failure and aplastic anemia with felbamate, fatal allergic rashes with lamotrigine, and serious visual field defects with vigabatrin. New AEDs with improved risk-benefit ratios are therefore needed for refractory epilepsy patients, 8 both as adjunctive treatment and in monotherapy.
SELETRACETAM
Preclinical beginnings
Seletracetam is a small-molecule AED (FIG. 1) , nonionized in water, and with solubility properties not expected to lead to any solubility-or dissolution-related absorption problems after oral administration.
Pharmacological background
Seletracetam is a structural analog of the antiepileptic drug levetiracetam, and its pharmacological activity appears to relate principally to an interaction with a novel binding site, synaptic vesicle protein 2A (SV2A). 9, 10 Seletracetam binds selectively, stereospecifically, and with high affinity (10- 10, 11 suggesting a functional correlation between binding and anticonvulsant activity. Seletracetam did not induce a significant displacement (Յ10 mol/L) of radioligands specific for the other known binding sites within the CNS (e.g., receptors, uptake systems, and ion channel proteins). 9 Thus, it appears that SV2A represents a novel molecular target that seems to have an important role in the pharmacological activity of seletracetam.
The effect of seletracetam on several voltage-dependent ionic and receptor-gated currents has been characterized. Seletracetam, like levetiracetam, does not appear to have any effect on voltage-dependent Na ϩ channels. 12 Likewise, seletracetam (1-100 mol/L) had no effect on voltage-gated K ϩ currents (both the A-type and the delayed rectifier) recorded in mouse hippocampal neurons in culture. 13 Seletracetam, like levetiracetam, appears to inhibit high-voltage-activated (HVA) Ca 2ϩ currents, but does not appear to modulate the low-voltage-activated (T-type) Ca 2ϩ currents. 14 Levetiracetam has been shown to inhibit the N-type channel 15 and possibly the P-type channel to a much smaller extent. 16 Seletracetam was found to be devoid of any direct effect on GABA-and strychnine-sensitive glycine-elicited currents, similarly to levetiracetam. 17 In contradistinction, seletracetam revealed a selectivity toward the glycine receptors (levetiracetam affects both). At pharmacologically relevant concentrations, seletracetam did not modify NMDA-, kainate-, or AMPA-induced currents. These data suggest that the pharmacological properties of seletracetam may derive principally from the potent and selective interaction of seletracetam with the SV2A protein, as well as from the moderate effects of the drug on calcium channels and strychnine-sensitive glycine receptors. The interface between the CNS binding site, SV2A, and these cellular effects is not known; correspondingly, whether any alleged interaction would exist, direct or indirect, is also unknown.
Activity in animal models of seizures and epilepsy
Seletracetam, like levetiracetam, shows no anticonvulsant activity in the two classical screening tests for AEDs: the maximal electroshock test (MES; tonic convulsions in the hind limbs) and the pentylenetetrazol test (PTZ; generalized clonic convulsions), both acute seizure models. 18 In distinct contrast, seletracetam shows potent seizure suppression in models of acquired or genetic epilepsy (TABLE 1) . 18 Seletracetam displayed potent protection against secondary generalized motor seizures in fully corneally kindled mice (ED 50 of 0.31 mg/ kg) and hippocampally kindled rats (minimal active dose, MAD, of 0.23 mg/kg). 18 The genetically sound-susceptible mouse model is an experimental genetic model of epilepsy, mimicking generalized reflex convulsive epilepsy in humans. Seletracetam provided dose-dependent protection in the genetically sound-susceptible mouse against clonic convulsions induced by an acoustic stimulus with an ED 50 of 0.17 mg/kg ( Genetic absence epilepsy rats from Strasbourg (GAERS) represent a strain of Wistar rats, originally selected by inbreeding, that are characterized by the spontaneous occurrence of EEG spike-and-wave discharges (SWDs) concomitant to behavioral arrest. 19 Based on both neurophysiological and pharmacological characterization of these rats, they appear to fully meet the requirements for an experimental model of nonconvulsive absence epilepsy in humans. Treatment of GAERS rats with seletracetam markedly suppressed their spontaneous SWDs, resulting in an ED 50 of 0.15 mg/kg i.p. 18 The results obtained from these two animal models representing primary generalized epilepsies demonstrate a potent and complete seizure suppression by seletracetam.
CNS tolerability in animals
The rotarod test of Dunham and Miya 20 is a classical test commonly used for determination and quantification of the minimal neurological deficit. In the rotarod test, seletracetam exhibits an even higher protective index than levetiracetam (the protective index, or the ratio of TD 50 for rotarod toxicity to ED 50 for seizure protection, is a measure of the separation between anticonvulsant potency and potency to induce motor impairment). 21 Previous studies revealed a high separation between doses induced significant rotarod impairment and seizure protection in both corneally kindled mice and GAERS rats when levetiracetam was compared with classical and newer AEDs. 22 Seletracetam impaired rotarod performance in corneally kindled mice (TD 50 ϭ 325 mg/kg) and GAERS rats (TD 50 ϭ 449 mg/kg). Compared with the protective ED 50 values obtained in the same animals, this resulted in an unusually high CNS tolerability margin of 1048 and 3075, respectively.
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Pharmacokinetic profile in animals
Seletracetam is rapidly and highly absorbed in animals, with linear and time-independent pharmacokinetics. 23 The exposure to the drug is similar in both sexes in all animal species tested. Plasma protein binding is low, and seletracetam is rapidly distributed to tissues. The major metabolic pathway of seletracetam, which has been observed in all tested species, consists of hydrolysis of the acetamide group to form the carboxylic acid metabolite ucb-101596-1, which is pharmacologically inactive. The parent compound, along with its major metabolite, is excreted mainly in urine. In vitro, seletracetam neither inhibits nor induces the major human drug metabolizing CYP isoenzymes and does not inhibit human epoxide hydrolase.
24,25
Toxicological information
Seletracetam has a low acute oral toxicity in rat and dog, and presents no significant CNS, cardiopulmonary, or respiratory tract effects, as demonstrated in the safety pharmacology studies. 26, 27 Repeated dosing of seletracetam in rat and dog showed that high doses of 2000 (mg/kg)/day in rat and Ն600 (mg/kg)/day in dog were not well tolerated. Drug-related effects were observed from dose levels of 20 (mg/kg)/day in rat and 50 (mg/ kg)/day in dog. Results of genotoxicity tests give no evidence for seletracetam being genotoxic at any of the doses and concentrations tested. The reproductive toxicology studies performed thus far have shown that seletracetam is neither embryotoxic nor teratogenic.
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Pharmacokinetics in humans
The pharmacokinetics of seletracetam was studied in healthy male subjects in a single rising-dose study, with doses ranging from 2-600 mg (FIG. 2) . 29 Seletracetam was rapidly absorbed, as demonstrated by a maximal plasma concentration (C max ) that was reached within 1 h after dosing in the majority of fasted subjects. Coadministration with a high-fat meal resulted in a delayed time to C max (median time delayed from 0.5 to 4 h after the dose) and a 39% reduction in C max , but had no effect on the overall extent of absorption. The disposition of seletracetam was characterized by linear pharmacokinetics over the 300-fold dose range studied.
The volume of distribution is approximately 0.6 L/kg, which is close to that of total body water. Seletracetam plasma terminal half-life is approximately 8 h in young healthy male subjects; it does not vary with dose. The total apparent clearance is approximately 67 mL/min, or approximately 0.8 (mL/min)/kg; this is much lower than the hepatic blood flow (1500 mL/min), indicating a low extraction ratio by the liver. Based on available in vitro data, there is a low potential for interaction of seletracetam on other drugs or of other drugs on seletracetam. Subjects in this study 29 reported adverse events typical of CNS drugs, including dizziness, somnolence, nausea, Rat MAD ϭ 0.23 mg/kg PO GAERS ϭ genetic absence epilepsy rats from Strasbourg, MAD ϭ minimal active dose, SWDs ϭ spike-and-wave discharges.
and headache. The incidence of dizziness tended to increase Ն50 mg; however, nausea, somnolence, and headache did not seem to be dose-related. All the adverse events reported were of mild or moderate intensity and the doses tested appeared to be well tolerated. A repeated-dose study was performed in 36 healthy male volunteers. 30 Subjects received either 20, 40, or 200 mg bid for 2 weeks. Seletracetam was shown to have predictable pharmacokinetics. Dose proportionality was confirmed for elimination and half-life. The metabolite concentrations were approximately 10-fold lower than those of the parent compound. After repeated dosing, no unexpected accumulation of either parent compound or metabolite was observed and no autoinduction of seletracetam clearance occurred, confirming time-independent pharmacokinetics. The subject-reported adverse events were similar to those observed in the single risingdose study, with CNS adverse events (AEs) reported most frequently-the majority of which were of mild to moderate intensity. In general, these AEs occurred within 1 h of initial dosing and decreased in incidence with subsequent dosing.
A study was conducted to investigate the excretion balance and metabolism of orally administered [14C]seletracetam (100 mg) in six healthy male volunteers. 31 Absorption of seletracetam administered as an oral solution is rapid and nearly complete (recovery of 92% of radioactive tracer in urine). The urine metabolic profiling indicated that, besides the parent compound, one major metabolite was identified (ucb-101596-1, the acidic metabolite) and two additional minor metabolites.
At 168 h, 3.21% of the dose was recovered in the feces and 91.9% of the dose was recovered in urine, reflecting a high absorption of the drug. In the urine, the unchanged compound (25%) and the major metabolite measured (53%) represented 78% of the dose.
In plasma, radioactivity was measurable until 72 h after the dose for all subjects. The major radioactive component was the parent drug, representing generally more than 90% of the circulating radioactivity up to 24 h after administration. The remaining radioactivity (up to 10%) was associated with ucb-101596-1, the acidic metabolite.
The blood cell/plasma ratio (0.5-0.7), computed up to 24 h, indicates some distribution with rapid and reversible equilibrium and no retention of [14C]-seletracetam in blood cells. Protein binding of radioactivity accounted for less than 10% at 1, 6, and 24 h after the dose. Overall, these results confirmed the pharmacokinetic parameters observed from previous studies. The AEs were mild and similar to those observed in the single and multiple rising-dose studies, with CNS adverse events reported most frequently.
AED therapy: efficacy versus tolerability
Given the apparent lack of difference in efficacy among AEDs, tolerability plays a key role when selecting AED therapy. 32 However, approximately 20 -30% of patients fail anticonvulsant therapy because of intolerable AEs. 33 Although complete seizure freedom is generally thought to be the most significant predictor of improved quality of life, 32 AEs may be the most important negative influence on a person's perception of individual current health status. 34 Indeed, significant AEs associated with established AEDs are estimated to contribute to initial treatment failure in Ͼ40% of patients. 34 The preclinical data obtained with seletracetam suggest a superior profile differentiating efficacious versus CNS-impairing doses that portends for a very potent anticonvulsant with a high CNS tolerability.
CONCLUSIONS
Seletracetam was chosen from a large portfolio of SV2A ligands based not only on its higher affinity for this binding site (10-fold greater affinity for SV2A than levetiracetam), but also on its potency and efficacy as observed in in vivo and in vitro testing. The mechanism whereby binding to SV2A results in anticonvulsant activity is as yet unknown. Like levetiracetam, seletracetam is not active in the traditional MES or PTZ models, but shows a potent ability to suppress seizure activity in animal models of acquired or genetic epilepsy. The linear, time-independent pharmacokinetics of the drug combined with a rapid and almost complete absorption indicate that seletracetam has a very uncomplicated pharmacokinetic profile. The initial human studies also indicate that seletracetam is well tolerated at high doses. Taken together, these results suggest that seletracetam represents a promising new AED candidate that demonstrates a potent and broad spectrum of seizure protection and high CNS tolerability in animal models, with initial clinical findings suggestive of straightforward pharmacokinetics and good tolerability.
